Open AccessUtilization of Telemetry System to Assess the Cardiovascular Profile of AH-1058, a New Cardioselective Ca2+ Channel Blocker, in Conscious Dogs
Author(s) -
Akira Takahara,
Hideki Dohmoto,
Ryota Yoshimoto,
Atsushi Sugiyama,
Keitaro Hashimoto
Publication year - 2001
Publication title -
japanese journal of pharmacology/japanese journal of pharmacology
Language(s) - English
Resource type - Journals
eISSN - 1347-3506
pISSN - 0021-5198
DOI - 10.1254/jjp.85.331
Subject(s) - telemetry , blood pressure , heart rate , medicine , cardiology , channel blocker , pharmacology , anesthesia , calcium , computer science , telecommunications
Cardiovascular effects of a new Ca2+ channel blocker AH-1058, 4-(5H-dibenzo[a,d]cyclo-hepten-5-ylidene)-1-[(E)-3-(3-methoxy-2-nitro)phenyl-2-propenyl]piperidine hydrochloride, were assessed in conscious dogs using a new telemetry system. AH-1058 (0.03, 0.1 and 0.3 mg/kg, i.v.) reduced systolic blood pressure and the maximal upstroke velocity of the left ventricular pressure and increased the heart rate in a dose-dependent manner without affecting the diastolic blood pressure; each of these responses lasted for several hours. These results support the previous knowledge that AH-1058 is a long-lasting cardiodepressive drug. The telemetry system provided important information for predicting favorable clinical effects of AH-1058.